VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
3607
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
649
Interactions with Platform & by Email
PARTICIPANTS
108
Unique # Participated
VALIDATIONS
49
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JUL 2020
TABLES
111
PAGES
163
EDITION
18
PRICE
USD $5450
The World of Fibromyalgia Therapeutics is Changing Fast!
It's Time to Identify Upcoming Revenue Pockets & Growth Areas.
Amid the COVID-19 crisis, the global market for Fibromyalgia Therapeutics estimated at US$2.8 Billion in the year 2020, is projected to reach a revised size of US$3.2 Billion by 2027, growing at a CAGR of 2% over the analysis period 2020-2027. Antiepileptics, one of the segments analyzed in the report, is projected to record a 1.8% CAGR and reach US$1.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antidepressants segment is readjusted to a revised 2.4% CAGR for the next 7-year period.
The Fibromyalgia Therapeutics market in the U.S. is estimated at US$749.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$613.1 Million by the year 2027 trailing a CAGR of 3.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.4% and 1.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.7% CAGR.
In the global Other Drug Classes segment, USA, Canada, Japan, China and Europe will drive the 1.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$311.3 Million in the year 2020 will reach a projected size of US$344.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$426.7 Million by the year 2027, while Latin America will expand at a 2.6% CAGR through the analysis period. We bring years of research experience to this 18th edition of our report. The 163-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Allergan plc; Boehringer Ingelheim GmbH; Daiichi Sankyo Company Limited; Eli Lilly and Company; Innovative Med Concepts Inc.; Pfizer Inc.; SWITCHBIOTECH LLC; Zynerba Pharmaceuticals Inc.
» Drug Class (Antiepileptics, Antidepressants, Other Drug Classes)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlassâ„¢ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Fibromyalgia Syndrome: A Prelude |
| Recent Market Activity |
| Fibromyalgia Therapeutics Market: A Nascent Sector |
| A Glance at the Current & Future Fibromyalgia Therapeutics Portfolio |
| FDA Approved Fibromyalgia Drugs |
| IMC-1: A Revolutionary Combination Therapy |
| Daiichi Sankyo’s Mirogabalin Drug Improvises on Lyrica |
| Tonix Pharma Develops Newer Sublingual Formulation of Cyclobenzaprine |
| Understanding Heightened Effect of Pain in Women Due to Fibromyalgia |
| Inconsistencies and Loopholes in Current Fibromyalgia Diagnoses |
| Fibromyalgia Treatment through High-Pressure Oxygen Application |
| EU approves New Device to Treat Fibromyalgia and Migraine |
| Global Competitor Market Shares |
| Fibromyalgia Therapeutics Competitor Market Share Scenario Worldwide (in %): 2020 & 2029 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Allergan plc (Ireland) |
| Boehringer Ingelheim GmbH (Germany) |
| Daiichi Sankyo Company Limited (Japan) |
| Eli Lilly and Company (USA) |
| Innovative Med Concepts, Inc. (USA) |
| Pfizer, Inc. (USA) |
| Pierre Fabre Médicament (France) |
| SWITCHBIOTECH LLC (USA) |
| Zynerba Pharmaceuticals, Inc. (USA) |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| Fibromyalgia Therapeutics Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Fibromyalgia Therapeutics Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 |
| Fibromyalgia Therapeutics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 |
| Antiepileptics (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025 |
| Antiepileptics (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 |
| Antiepileptics (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Antidepressants (Drug Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 |
| Antidepressants (Drug Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 |
| Antidepressants (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 |
| Other Drug Classes (Drug Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 |
| Other Drug Classes (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 |
| Other Drug Classes (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| United States |
| Market Facts & Figures |
| US Fibromyalgia Therapeutics Market Share (in %) by Company: 2020 & 2025 |
| United States Fibromyalgia Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025 |
| Fibromyalgia Therapeutics Market in the United States by Drug Class: A Historic Review in US$ Million for 2009-2017 |
| United States Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Canada |
| Canadian Fibromyalgia Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025 |
| Canadian Fibromyalgia Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017 |
| Fibromyalgia Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| Japan |
| Japanese Market for Fibromyalgia Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025 |
| Fibromyalgia Therapeutics Market in Japan: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017 |
| Japanese Fibromyalgia Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| China |
| Chinese Fibromyalgia Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025 |
| Fibromyalgia Therapeutics Historic Market Analysis in China in US$ Million by Drug Class: 2009-2017 |
| Chinese Fibromyalgia Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Europe |
| Market Facts & Figures |
| European Fibromyalgia Therapeutics Market: Competitor Market Share Scenario (in %) for 2020 & 2025 |
| European Fibromyalgia Therapeutics Market Demand Scenario in US$ Million by Region/Country: 2018-2025 |
| Fibromyalgia Therapeutics Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 |
| European Fibromyalgia Therapeutics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 |
| European Fibromyalgia Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025 |
| Fibromyalgia Therapeutics Market in Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017 |
| European Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| France |
| Fibromyalgia Therapeutics Market in France by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025 |
| French Fibromyalgia Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017 |
| French Fibromyalgia Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Germany |
| Fibromyalgia Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| German Fibromyalgia Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| German Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Italy |
| Italian Fibromyalgia Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025 |
| Fibromyalgia Therapeutics Historic Market Analysis in Italy in US$ Million by Drug Class: 2009-2017 |
| Italian Fibromyalgia Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| United Kingdom |
| United Kingdom Market for Fibromyalgia Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025 |
| Fibromyalgia Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017 |
| United Kingdom Fibromyalgia Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Spain |
| Spanish Fibromyalgia Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025 |
| Spanish Fibromyalgia Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017 |
| Fibromyalgia Therapeutics Market in Spain: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| Russia |
| Russian Fibromyalgia Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025 |
| Fibromyalgia Therapeutics Market in Russia by Drug Class: A Historic Review in US$ Million for 2009-2017 |
| Russian Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Europe |
| Rest of Europe Fibromyalgia Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025 |
| Fibromyalgia Therapeutics Market in Rest of Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017 |
| Rest of Europe Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Asia-Pacific |
| Asia-Pacific Fibromyalgia Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Fibromyalgia Therapeutics Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017 |
| Asia-Pacific Fibromyalgia Therapeutics Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 |
| Fibromyalgia Therapeutics Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Asia-Pacific Fibromyalgia Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017 |
| Asia-Pacific Fibromyalgia Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Australia |
| Fibromyalgia Therapeutics Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| Australian Fibromyalgia Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| Australian Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| India |
| Indian Fibromyalgia Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025 |
| Indian Fibromyalgia Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017 |
| Fibromyalgia Therapeutics Market in India: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| South Korea |
| Fibromyalgia Therapeutics Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| South Korean Fibromyalgia Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| Fibromyalgia Therapeutics Market Share Distribution in South Korea by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Asia-Pacific |
| Rest of Asia-Pacific Market for Fibromyalgia Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025 |
| Fibromyalgia Therapeutics Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017 |
| Rest of Asia-Pacific Fibromyalgia Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Latin America |
| Latin American Fibromyalgia Therapeutics Market Trends by Region/Country in US$ Million: 2018-2025 |
| Fibromyalgia Therapeutics Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017 |
| Latin American Fibromyalgia Therapeutics Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 |
| Latin American Fibromyalgia Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025 |
| Fibromyalgia Therapeutics Historic Market Analysis in Latin America in US$ Million by Drug Class: 2009-2017 |
| Latin American Fibromyalgia Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Argentina |
| Argentinean Fibromyalgia Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025 |
| Fibromyalgia Therapeutics Market in Argentina in US$ Million by Drug Class: A Historic Review for the Period 2009-2017 |
| Argentinean Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Brazil |
| Fibromyalgia Therapeutics Market in Brazil by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Brazilian Fibromyalgia Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017 |
| Brazilian Fibromyalgia Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Mexico |
| Fibromyalgia Therapeutics Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| Mexican Fibromyalgia Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| Mexican Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Latin America |
| Rest of Latin America Fibromyalgia Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025 |
| Fibromyalgia Therapeutics Market in Rest of Latin America by Drug Class: A Historic Review in US$ Million for 2009-2017 |
| Rest of Latin America Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Middle East |
| The Middle East Fibromyalgia Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Fibromyalgia Therapeutics Market in the Middle East by Region/Country in US$ Million: 2009-2017 |
| The Middle East Fibromyalgia Therapeutics Market Share Breakdown by Region/Country: 2009, 2019, and 2025 |
| The Middle East Fibromyalgia Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025 |
| The Middle East Fibromyalgia Therapeutics Historic Market by Drug Class in US$ Million: 2009-2017 |
| Fibromyalgia Therapeutics Market in the Middle East: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| Iran |
| Iranian Market for Fibromyalgia Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025 |
| Fibromyalgia Therapeutics Market in Iran: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017 |
| Iranian Fibromyalgia Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Israel |
| Israeli Fibromyalgia Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025 |
| Fibromyalgia Therapeutics Market in Israel in US$ Million by Drug Class: A Historic Review for the Period 2009-2017 |
| Israeli Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Saudi Arabia |
| Saudi Arabian Fibromyalgia Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025 |
| Fibromyalgia Therapeutics Historic Market Analysis in Saudi Arabia in US$ Million by Drug Class: 2009-2017 |
| Saudi Arabian Fibromyalgia Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| United Arab Emirates |
| Fibromyalgia Therapeutics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| United Arab Emirates Fibromyalgia Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| Fibromyalgia Therapeutics Market Share Distribution in United Arab Emirates by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Middle East |
| Fibromyalgia Therapeutics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| Rest of Middle East Fibromyalgia Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| Rest of Middle East Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Africa |
| African Fibromyalgia Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025 |
| Fibromyalgia Therapeutics Market in Africa by Drug Class: A Historic Review in US$ Million for 2009-2017 |
| African Fibromyalgia Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 22 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com